Similar Search Results

The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry

Banerjee, Tannista; Siebert, Ralph - CESifo - 2014

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

Persistent link: https://www.econbiz.de/10010734328

Margins and Market Shares: Pharmacy Incentives for Generic Substitution

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2012

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

Persistent link: https://www.econbiz.de/10010603857

Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?

Brekke, Kurt R.; Grasdal, Astrid L.; Holmås, Tor Helge - CESifo - 2007

-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel …

Persistent link: https://www.econbiz.de/10005406112

Reference Pricing of Pharmaceuticals

Brekke, Kurt R.; Königbauer, Ingrid; Straume, Odd Rune - CESifo - 2006

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry...

Persistent link: https://www.econbiz.de/10005406396

Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment

Brekke, Kurt R.; Holmås, Tor Helge; Straume, Odd Rune - CESifo - 2010

We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical...

Persistent link: https://www.econbiz.de/10008799730

Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010

Lichtenberg, Frank - CESifo - 2015

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months)-—about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

Persistent link: https://www.econbiz.de/10011122677

The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data

Lichtenberg, Frank; Pettersson, Billie - CESifo - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

Persistent link: https://www.econbiz.de/10010569681

Corporate Philanthropy and Productivity: Evidence from an Online Real Effort Experiment

Tonin, Mirco; Vlassopoulos, Michael - CESifo - 2014

Contributing to a social cause can be an important driver for workers in the public and non-profit sector as well as in firms that engage in Corporate Philanthropy or other Corporate Social Responsibility policies. This paper compares the effectiveness of social incentives - that take the form...

Persistent link: https://www.econbiz.de/10010764293

Sources of Productivity Spillovers: Panel Data Evidence from China

Baltagi, Badi H.; Egger, Peter; Kesina, Michaela - CESifo - 2014

This paper assesses sources of productivity spillovers in China’s electric and electronic manufacturing industry using a rich panel data-set of 25,360 firms observed over the period 2004-2007. This industry is characterized by its important reliance on technology. In particular, the paper...

Persistent link: https://www.econbiz.de/10010877809

The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence

Lichtenberg, Frank; Hostenkamp, Gisela - CESifo - 2013

important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma … post-1997 chemotherapy innovation did not exceed $45,551.We also investigate the impact of chemotherapy innovation on the …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

Persistent link: https://www.econbiz.de/10010723537